The 2009 Fall Clinical Dermatology Conference convened October 15-18 in Las Vegas where psoriasis experts, such as Mark Lebwohl, M.D. and Alice Gottlieb, M.D. provided clinical updates on psoriasis management, including the use of topical medications (corticosteroids, Vectical) and biologics, such as the TNF Inhibitors (Amevive, Enbrel, Humira, Remicade) and a new biologic, Stelara, that blocks IL-12 and IL-23 that are associated with inflammation the the overgrowth of skin cells.
Some of the key points discussed included the importance for dermatologists to inquire about symptoms of psoriatic arthritis. Given the risk that long-term disability that may be caused by psoriatic arthritis, it is critical that any psoriasis therapy for a patient with arthritic symptoms, also help to minimize joint damage.